Core Viewpoint - Northeast Pharmaceutical is enhancing shareholder engagement through a promotional event for its new beauty products, aiming to showcase its latest achievements in the health sector and establish a long-term shareholder return mechanism [1][2] Group 1: Shareholder Engagement Activities - The company plans a shareholder reward event from December 25 to December 28, 2025, to help shareholders understand its new beauty products [1] - Eligible shareholders must hold at least 500 shares as of December 8, 2025, and can participate in the event to receive exclusive offers [1] - Shareholders will enjoy a "buy 1 get 4" promotion along with a 10% discount on the total purchase, enhancing the value of their investment [1] Group 2: Business Development in Health Sector - Northeast Pharmaceutical is focusing on the health sector, launching the functional skincare brand "Qifangyuan" to integrate skin health with pharmaceutical technology [2] - The brand leverages the company's national-level technology center and collaborates with research institutes in Shenyang, Beijing, and Shanghai to create a coordinated R&D matrix [2] - The company is expanding into the food and health sector with products like medicinal biscuits, aiming to meet diverse health needs and strengthen its health product matrix [2]

Core Viewpoint - Northeast Pharmaceutical is focusing on market trends, leveraging its two core sales segments, raw materials and formulations, to achieve significant results and ensure stable performance for the company [1] Raw Material Segment - Northeast Pharmaceutical is a key global supplier of raw materials, enhancing its international market competitiveness, particularly in the EU and Japan/Korea, with market share increasing year by year [2] - The raw material sales company demonstrated strong market capabilities in Q4, with profits exceeding planned targets for two consecutive months in October and November, particularly in November [2] - Key products such as Vitamin C and L-Carnitine exceeded sales targets, while other products like Amantadine and Piracetam also performed well, enhancing the product matrix's competitiveness [2] - The company actively participated in major industry exhibitions to connect with core customer needs and adjust market strategies based on competitor insights [2][3] Formulation Segment - Northeast Pharmaceutical's formulation products rank first in domestic sales, contributing to economic benefits and enhancing brand recognition [4] - The formulation sales company is focusing on maintaining and expanding the market competitiveness of key products, with systematic planning for products like Gut Health and Pain Relief tablets [4] - Efficient execution and collaboration among teams have led to achieving monthly performance targets, providing confidence for year-end goals [4][5] Expansion into New Fields - In Q4, Northeast Pharmaceutical made significant strides in the health sector by launching new products such as health biscuits and advancing the development of additional health-oriented snacks [6] - The company is exploring the beauty sector with functional skincare products, leveraging its pharmaceutical-grade standards in product development [6] - The company aims to optimize its health product matrix and explore comprehensive health services, creating new growth points [6]

Core Insights - The company is focusing on market trends, with its two core sales segments, raw materials and formulations, playing a significant role in stabilizing performance and achieving important results in market penetration [1][2] - The company is actively expanding in the health sector, launching new products that contribute to comprehensive health services, providing confidence and direction for future work [1][4] Raw Material Segment - The company is a key global supplier of raw materials, enhancing its international market competitiveness, particularly in the EU and Japan, with market share increasing year by year [1][2] - In Q4, the raw material sales company demonstrated strong market capabilities, exceeding profit targets in October and November, with notable performance in November [1][2] - Key products such as Vitamin C and L-Carnitine significantly outperformed sales targets, indicating a strengthening product matrix [1][2] Market Expansion and Management - The raw material sales company has actively participated in major industry exhibitions to engage with core customers and align market orders, while also monitoring industry trends and competitor dynamics [2] - Internal management has been enhanced, with a focus on accountability and improving business capabilities, leading to effective collaboration across departments [2] Formulation Segment - The company has several formulation products that rank first in domestic sales, contributing to economic benefits and enhancing brand recognition [3] - A systematic approach has been adopted to boost sales of key products, with effective execution leading to monthly performance improvements [3] New Product Development - In Q4, the company made significant strides in the health sector by launching new products such as health-oriented biscuits, while also developing additional products to meet diverse health needs [4] - The company is leveraging its experience in R&D and quality control to explore the health food sector, including functional skincare products that integrate pharmaceutical technology [4][5] Strategic Focus - The company aims to leverage its comprehensive advantages in innovation, resource allocation, and market positioning to optimize its health product matrix and explore new growth points in the health sector [5]

Core Viewpoint - Northeast Pharmaceutical (000597.SZ) is launching a shareholder reward program to express gratitude to shareholders and enhance their understanding of the company's intrinsic value while promoting its new beauty products [1] Group 1: Shareholder Reward Program - The company is initiating a "shareholder reward activity" to thank shareholders for their long-term support [1] - The program includes a dual surprise offer for eligible shareholders, which involves downloading the "Enterprise WeChat APP" and entering a company-specific WeChat group for identity verification [1] - Shareholders can unlock a "buy 1 get 4" offer on the company's proprietary "Qifangyuan" beauty product series, along with an exclusive 10% discount [1] Group 2: Promotional Details - The dual benefits are available from December 25, 2025, to December 28, 2025, exclusively on the company's authorized online store [1] - Each order is limited to one 10% discount coupon, which cannot be exchanged for cash or combined with other non-shareholder exclusive offers [1] - The discount coupon will automatically expire if not used within the specified period [1]

Core Viewpoint - Northeast Pharmaceutical (000597) announced a shareholder reward activity to express gratitude for shareholder support and enhance understanding of the company's intrinsic value while promoting its own beauty brand [1] Group 1 - The shareholder reward activity will take place from December 25 to December 28, 2025 [1] - The activity is open to shareholders who hold at least 500 shares as of the market close on December 8, 2025 [1] - The promotional offers include "buy 1 get 4" and an exclusive 10% discount [1]

证券代码:000597 证券简称:东北制药 公告编号:2025-079 一、活动时间 本次活动时间为 2025年 12 月 25 日00:00:00 至2025 年 12 月 28日 23:59:59。 股东未在 2025 年 12 月 28 日 23:59:59 前完成申领及使用的，视为自动放弃本次 参与资格。 二、参加活动股东范围 于 2025 年 12 月 8 日下午收市时在中国证券登记结算有限责任公司深圳分公 司登记在册的持有公司股份 500 股（含）以上的股东，可以参与本次股东回馈活 动。 公司将在活动期间内不定期主动更新股东信息，未在前述股东名册中的现有 持股股东，亦可通过有效的股东持股证明文件享有本次活动权益。 三、活动内容 东北制药集团股份有限公司 关于股东回馈活动的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）为建立长效、多样的股东 回报机制，感谢广大股东长期以来对公司的支持，提高股东对公司内在价值的理 解与认识，同时，让股东更好地了解公司新投放市场的"栖芳源紧致焕颜精粹水" ...

证券代码：000597 证券简称：东北制药 公告编号：2025-077 东北制药集团股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．本次股东会未出现否决议案的情形； 2．本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.本次会议召开的时间： （1）现场会议召开时间：2025 年 12 月 15 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 15 日 9:15 至 9:25，9:30 至 11:30，13:00 至 15:00；通过深圳证券 交易所互联网投票系统进行网络投票的具体时间为 2025 年 12 月 15 日 9:15 至 15:00。 2.现场会议地点：沈阳经济技术开发区昆明湖街 8 号，东北制药集团股份有 限公司。 3.召开方式：采用现场表决与网络投票相结合的方式召开。 4.召集人：公司董事会 5.主持人：公司董事长周凯先生 6.本次股东会会议召开符合有关法律、行政法规、部门规 ...

Group 1 - The company has established a management system for related party transactions to standardize practices and protect the interests of the company and all shareholders [1] - The definition of related parties includes both legal entities and individuals, with clear delineation of related relationships and transaction scopes [1] - Different amounts of related party transactions require approval from the shareholders' meeting, board of directors, or general manager's office, with related directors and shareholders required to abstain from voting during the review [1] Group 2 - The company has set standards and content for the disclosure of related party transactions, such as transactions exceeding 300,000 yuan with individuals or 3 million yuan with legal entities, which account for more than 0.5% of net assets, must be disclosed in a timely manner [1] - The management system will take effect after being approved by the shareholders' meeting [1]

证券代码：000597 证券简称：东北制药 公告编号：2025-078 东北制药集团股份有限公司 关于回购注销部分限制性股票减少注册资本 暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）于 2025 年 3 月 5 日召开第 九届董事会第三十七次会议、第九届监事会第二十五次会议；2025 年 12 月 15 日 召开 2025 年第二次临时股东会，审议通过了《关于拟回购注销 2022 年限制性股 票激励计划部分已获授但尚未解除限售的限制性股票的议案》。公司拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除限售的限制性股票 160,000 股。 具体内容详见 2025 年 3 月 6 日刊登于《证券时报》《中国证券报》《上海证券报》 以及巨潮资讯网上的《东北制药集团股份有限公司关于拟回购注销 2022 年限制性 股票激励计划部分已获授但尚未解除限售的限制性股票的公告》（公告编号： 2025-011）。 本次回购注销完成后，公司总股本将减少 160,000 股，注册资本将相应减少 160, ...

北京德恒律师事务所 关于东北制药集团股份有限公司 北京德恒律师事务所 关于东北制药集团股份有限公司 2025 年第二次临时股东会的法律意见 2025 年第二次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于东北制药集团股份有限公司 2025 年第二次临时股东会的 法律意见 德恒 01G20240159 号 致：东北制药集团股份有限公司 东北制药集团股份有限公司（以下简称"公司"）2025 年第二次临时股东 会（以下简称"本次会议"）于 2025 年 12 月 15 日（星期一）召开。北京德恒 律师事务所接受公司委托，指派李哲律师、王冰律师（以下简称"德恒律师"） 出席本次会议。根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《东北制药集团股份有限公司章程》（以下 简称"《公司章程》"）的规定，德恒律师就本次会议的召集、召开程序、现场 出席会议人员资格、表决 ...